Recently Featured

Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat

April 18, 2026
The U.S. Court of Appeals has reinstated a $177 million verdict in favor of Teva Pharmaceuticals, reversing a prior decision that had dismissed the company’s claims against Eli Lilly regarding patent infringement in the migraine medication sector. This ruling marks a significant shift in the ongoing litigation between the two pharmaceutical giants, which has seen…

Innovators Overcome Barriers to Advance In Vivo Cell Therapy

April 18, 2026
As in vivo cell therapies progress into clinical trials, a new wave of innovators is addressing the technical and logistical challenges that have historically hindered their commercial viability. These therapies, which aim to deliver therapeutic cells directly into the body, promise significant advancements in treatment options for various diseases, including cancer and genetic disorders. However,…

Daiichi Sankyo and Interna Partner for MNM-Targeted Delivery Solutions

April 18, 2026
Daiichi Sankyo has entered into a strategic partnership with Interna Therapeutics to develop advanced targeted delivery solutions utilizing molecular nano motor (MNM) technology. This collaboration aims to enhance the precision of drug delivery systems, potentially improving therapeutic outcomes in various disease states. The integration of MNM technology into drug delivery mechanisms represents a significant advancement…

Cell Therapy Shows Promise in Liver Transplant Immunotolerance, Study Reveals

April 18, 2026
A recent small-scale study has demonstrated that cell therapy may enhance immune tolerance in liver transplant patients, potentially reducing the need for lifelong immunosuppressive therapy. Conducted with living donors, the research indicates that using cells from donors’ white blood cells can help recipients’ immune systems recognize transplanted liver fragments as their own, thereby mitigating the…

Ongoing Cases